Crescita Therapeutics and NanoPass have entered an exclusive distribution agreement to introduce MicronJetTM600, an advanced intradermal delivery device, to the Canadian market. MicronJet’s innovative design leverages MEMS technology to provide a consistent, effective, and painless delivery of aesthetic products and therapeutic substances.

Featuring three 0.6mm silicon pyramids, MicronJet enables precise administration to delicate areas such as the face, neck, and décolleté. It eliminates bruising and discomfort, providing a comfortable injection experience for practitioners and patients.

Crescita will pursue regulatory approval from Health Canada and anticipates the product launch in the first half of 2025. MicronJet has received worldwide recognition, with over 70 clinical studies and peer-reviewed publications supporting its efficacy. It is CE-marked, FDA-cleared, ISO 13485 certified, and approved in Australia and other regions.

Crescita Therapeutics (TSX: CTX, OTC US: CRRTF) is a Canadian dermatology company that commercializes innovative, science-based products. NanoPass is a pioneer in intradermal delivery technology, developing cutting-edge devices to enhance the effectiveness and precision of aesthetic treatments.

Source link: http://www.businesswire.com/news/home/20240717950170/en/Crescita-Expands-Medical-Aesthetic-Portfolio-with-MicronJetTM600-The-World%E2%80%99s-Smallest-Intradermal-Delivery-Device

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.